Appili Therapeutics Inc. (OTCMKTS:APLIF) Sees Significant Increase in Short Interest

Appili Therapeutics Inc. (OTCMKTS:APLIF) saw a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 56,600 shares, an increase of 625.6% from the October 31st total of 7,800 shares. Based on an average daily volume of 326,400 shares, the short-interest ratio is currently 0.2 days.

Appili Therapeutics Stock Up 16.5 %

Shares of OTCMKTS:APLIF traded up $0.00 during midday trading on Wednesday, reaching $0.03. The company’s stock had a trading volume of 9,853 shares, compared to its average volume of 98,771. Appili Therapeutics has a 12-month low of $0.01 and a 12-month high of $0.05. The firm has a 50 day moving average of $0.02 and a 200-day moving average of $0.03.

About Appili Therapeutics

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.